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Edited by Varda RotterAbstract Functional loss of p53 and ErbB2 overexpression are
the frequent genetic alterations in human breast carcinomas.
Here, we found that ErbB2 expression was upregulated in pri-
mary cultured mammary epithelial cells (MECs) isolated from
mice with a defect in exons 5 and 6 of the p53 gene (p53D5,6).
The reporter gene activity in the p53D5,6 MECs transfected with
the 756 bp ﬂanking region of the hErbB2 gene was higher than
the wild type MECs. p53 inactivation selectively increased the
level of AP-2a, but not AP-2b and AP-2c and a mutation of
the two AP-2 binding sites completely inhibited the reporter
activity.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein kinase A1. Introduction
Breast cancer is one of the most common malignancies in
Western women. Human breast tumors arise from normal cells
as a result of the accumulation of multiple mutations of tumor
suppressor genes such BRCA and p53 [1]. p53 is a transcription
factor that controls the cellular stress response [2,3]. A defect
in the function of p53 is the most frequent genetic alteration
in human tumors. Germ-line mutations of p53, which are pre-
dominantly amino acid substitutions within the DNA binding
domain, have been linked to 70% of families with Li–Fraumeni
syndrome. These patients have a high risk of early-onset breast
cancers as well as other tumors [4,5]. Indeed, a mutation of the
p53 gene is frequently found in human breast carcinomas.
Approximately 30–50% of breast cancers carry a mutation in
the p53 gene and show p53 protein expression by immunohis-
tochemistry [6].
Activational mutations of oncogenes also play a key role in
breast carcinogenesis. One of the most important activational
mutations involves the ErbB2/HER-2/neu gene, which is a
member of the epidermal growth factor receptor (EGFR) fam-
ily of tyrosine kinase receptors. The overexpression of ErbB2 is
a common event in breast cancer [7]. An inverse relationship
between the estrogen response and EGFR/ErbB2 expression
in clinical breast cancer has been reported, with ErbB2
overexpression being associated with a decreased sensitivity
to anti-estrogen (tamoxifen) therapy and a poor prognosis*Corresponding author. Fax: +82 62 222 5414.
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doi:10.1016/j.febslet.2006.10.059[8,9]. Herceptin (Trastuzumab), which is anti-ErbB2 mono-
clonal antibody, has been shown to be active as either a single
agent or in combination with chemotherapy for ErbB2-posi-
tive metastatic breast cancer [10]. Moreover, it is also useful
in diminishing the level of tamoxifen resistance of breast can-
cer [11,12]. Hence, the expression levels of the ErbB2 gene are
closely related to successful chemotherapy against breast can-
cer.
Previously, two lines of mouse models of breast cancer were
established by the conditional knockout of p53 genes through
the Cre–loxP recombination system in the mammary glands of
mice [13]. In this system, two lines of mice are required: one
carrying the ﬂoxed p53 alleles (p53fp/fp) and the other express-
ing Cre recombinase under the regulation of the whey acidic
protein (WAP) promoter (WAP-Cre). Cre expression leads
to a recombination within the lox P sequences placed within in-
trons 4 and 6 of the p53 gene, which results in a deletion of a
part of the DNA binding domain (exons 5 and 6) of p53 that
inactivates the gene (p53D5,6). It was found that many charac-
teristics of these mouse models resemble human breast cancer.
In particular, the expression levels of the ErbB2 gene were
obviously increased in the mammary tumor lysates obtained
from the p53D5,6 mice [13]. In clinical studies, ErbB2 overex-
pression in breast cancer tissues, which is associated with in-
creased proliferation, is often observed in tumors with p53
alterations [14].
Despite both p53 and ErbB2 being crucial factors for the
pathological progress of breast cancer, the precise role of
p53 in ErbB2 expression during mammary tumorigenesis is un-
clear. This paper shows for the ﬁrst time that ErbB2 expression
is upregulated in mammary epithelial cells (MEC) from p53D5,6
mice, in which the induction of AP-2a through the sustained
activation of protein kinase A (PKA) is a key step.2. Materials and methods
2.1. Materials
U0126 was supplied by Cell Signaling Technology (Beverly, MA).
The anti-AP-2b and AP-2c antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). The antibodies against AP-2a, p53
and ErbB2 were obtained from Upstate Inc. (Charlottesville, VA),
Novocastra Laboratory Ltd. (Newcastle, UK) and DakoCytomation
(Glostrup, Denmark), respectively. The alkaline phosphatase and
horseradish peroxidase-conjugated donkey anti-mouse, anti-rabbit
and anti-goat IgGs were acquired from Jackson ImmunoResearch
(West Grove, PA). 5-Bromo-4-chloro-3-indoylphosphate/nitroblue tet-
razolium and pRL-SV40 plasmid were purchased from Promega (Mad-
ison, WI). The H-89 was supplied by Calbiochem (La Jolla, CA). The
anti-actin antibody and the other reagents in the molecular studies
were obtained from Sigma Chemical (St. Louis, MO). The plasmids,
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provided by Dr. Winkler R. (University of Liege, Belgium) [15].2.2. Generation of WAP-Cre p53fp/fp mice and mammary epithelial cell
(MEC) culture
WAP-Cre mice were mated with p53fp/fp mice, and the Cre mediated
recombination and p53 deletion were conﬁrmed by PCR analysis and
x-gal staining, as published in previous report [13]. The MECs were
isolated from the number 4 mammary gland from the 6-month-old
p53fp/fp or WAP-Cre p53fp/fp mice using a slight modiﬁcation of a pre-
viously published method [16]. After washing with sterile PBS, the
mammary gland was minced gently with two knives and dissociated
in the presence of 0.15% collagenase for 12 h at 37 C. The cells was
collected and embedded in a fetuin-coated plastic dish and maintained
in F-12/DMEM containing 10 ng/ml epidermal growth factor (EGF),
1 lg/ml insulin, 15% fetal calf serum, 100 U/ml penicillin and 100 lg/
ml streptomycin at 37 C in a humidiﬁed atmosphere containing 5%
CO2. The cells used for the experiments were from up to 10 passages.2.3. Preparation of nuclear fraction
The nuclear extracts were prepared according to the method re-
ported by Schreiber et al. [17]. Brieﬂy, the cells in dishes were washed
with ice-cold PBS. The cells were then scraped, transferred to micro-
tubes, and allowed to swell after adding 100 ll of a lysis buﬀer contain-
ing 10 mMHEPES (pH 7.9), 0.5% Nonidet P-40, 10 mMKCl, 0.1 mM
EDTA, 1 mM dithiothreitol and 0.5 mM phenylmethylsulfonylﬂuo-
ride. The cell membranes were disrupted by vortexing, and the lysates
were incubated for 10 min on ice and centrifuged at 7200 · g for 5 min.
The pellets containing the crude nuclei were resuspended in 100 ll of
an extraction buﬀer containing 20 mM HEPES (pH 7.9), 400 mM
NaCl, 1 mM EDTA, 1 mM dithiothreitol and 1 mM phen-
ylmethylsulfonylﬂuoride, and then incubated for 30 min on ice. The
samples were centrifuged at 15800 · g for 10 min in order to obtain
the supernatants containing the nuclear extracts. The nuclear extracts
were stored at 80 C until needed.2.4. Immunoblot analysis
Sodium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis
and immunoblot analysis were performed according to the procedures
reported in the literature [18]. The cells were lysed in a buﬀer contain-
ing 20 mM Tris–Cl (pH 7.5), 1% Triton X-100, 137 mM sodium chlo-
ride, 10% glycerol, 2 mM EDTA, 1 mM sodium orthovanadate,
25 mM b-glycerophosphate, 2 mM sodium pyrophosphate, 1 mM
phenylmethylsulfonylﬂuoride and 1 lg/ml leupeptin. The cell lysates
were centrifuged at 10000 · g for 10 min to remove the debris. The
proteins were fractionated using a 10% separating gel. Brieﬂy, the frac-
tionated proteins were transferred electrophoretically to nitrocellulose
paper. The proteins were immunoblotted with each speciﬁc antibody.
The secondary antibodies used were horseradish peroxidase- or alka-
line phosphatase-conjugated anti-IgG antibody. The nitrocellulose
paper was developed using 5-bromo-4-chloro-3-indolylphosphate/4-
nitroblue tetrazolium chloride or developed using an ECL chemilumi-
nescence system.
2.5. Reporter gene assay
A dual-luciferase reporter assay system (Promega, Madison, WI)
was used to determine the promoter activity. Brieﬂy, the cells were
transiently transfected with 1 lg of p756-Luc, p756m-Luc or p53-
Luc (Stratagene, La Jolla, CA) plasmid and 20 ng of pRL-SV40
plasmid (Renilla luciferase expression for normalization) (Promega,
Madison, WI) using the Genejuice Reagent (Novagen, Madison,
WI). The ﬁreﬂy and Renilla luciferase activities in the cell lysates were
measured using a luminometer (Turner Designs; TD-20, CA). The rel-
ative luciferase activity was calculated by normalizing the ErbB2 pro-
moter-driven ﬁreﬂy luciferase activity to that of Renilla luciferase.
2.6. Gel shift analysis
A double stranded oligonucleotide containing the putative AP-2
binding site was used for gel shift analysis after end-labeling the probe
with [c-32P]ATP and T4 polynucleotide kinase. The promoter region of
the ErbB2 gene contains a putative AP-2 binding site, which induces the
strong activation of ErbB2 gene transcription in BT-474 cells [15]. The
sequences of the AP-2 consensus oligonucleotide was 5 0-GAGA-ACGGCTGCAGGCAACCCAGG-3 0. The reaction mixtures con-
tained 4 ll of a 5 · binding buﬀer containing 20% glycerol, 5 mM
MgCl2, 250 mM NaCl, 2.5 mM EDTA, 2.5 mM dithiothreitol,
0.25 mg/ml poly dI–dC and 50 mM Tris–Cl (pH 7.5), 10 lg of nuclear
extracts and sterile water in a total volume of 20 ll. The reaction mix-
tures were preincubated for 10 min. The DNA-binding reactions were
carried out at room temperature for 20 min after adding a 1 ll probe
(106 cpm). The speciﬁcity of binding was determined using competition
experiments, which were carried out by adding a 20-fold excess of the
unlabeled AP-2 oligonucleotide to the reaction mixture before the
DNA-binding reaction. For the immuno-inhibition assay, the antibod-
ies against AP-2a or AP-2c (1 lg each) were added to the reaction mix-
ture. The samples were loaded onto 4% polyacrylamide gels at 100 V.
The gels were removed and dried, and imaged by autoradiography.2.7. Reverse transcription-polymerase chain reaction (RT-PCR)
The total RNA was isolated using total RNA isolation kit (RNA-
gents, Promega, Madison, WI). The total RNA (1.0 lg) obtained
from the cells was reverse-transcribed using an oligo(dT) 18mer as a
primer and M-MLV reverse transcriptase (Bioneer, Eumsung, Korea)
to produce the cDNAs. PCR was performed using the selective primers
for the mouse AP-2a and S16 ribosomal protein (S16r) genes. The
PCRs were carried out for 35 cycles using the following conditions:
denaturation at 98 C for 10 s, annealing at 50 C for 0.5 min, and
elongation at 72 C for 1 min. The band intensities of the ampliﬁed
DNAs were compared after visualization on a UV transilluminator.2.8. Data analysis
Scanning densitometry was carried out using an Image Scan and
Analysis System (FLA-7000, Fujiﬁlm, Japan). One-way analysis of
variance (ANOVA) was used to assess the signiﬁcant diﬀerences be-
tween the treatment groups. The Newman–Keuls test was used to com-
pare the multiple group means for each signiﬁcant eﬀect of treatment.
The criterion for statistical signiﬁcance was set at either P < 0.05 or
P < 0.01.3. Results
3.1. Enhanced expression of ErbB2 in p53-inactivated MEC
The MEC used were isolated from the 6-months-old p53fp/fp
or WAP-Cre p53fp/fp mice. The presence of loxP sites in introns
4 and 6 did not interfere with the transcription of p53, and the
full-length p53 protein was detected in the doxorubicin (3 or
10 lM)-treated p53fp/fp MECs (Fig. 1A). A smaller protein
product with the expected mass of 39 kDa, which was desig-
nated p53D5,6 by Cre recombination was detected in the
WAP-Cre p53fp/fp MECs (Fig. 1A) [13]. After exposing the
cells to doxorubicin (1 or 3 lM) for 18 h, the p53-dependent
reporter transcription was concentration-dependently in-
creased in the wild type p53fp/fp MECs transiently transfected
with the p53-Luc reporter plasmid (Fig. 1B). In contrast,
p53D5,6 is transcriptionally inactive and the p53-reporter activ-
ity was lower in the p53D5,6 MECs. This shows that p53 in the
p53D5,6 MECs was truncated at the DNA binding site of p53
(exons 5 and 6) and was transcriptionally inactive.
The ErbB2 expression levels in both p53fp/fp MEC and
p53D5,6 MEC were then compared. The basal expression level
of ErbB2 in the p53D5,6 MEC was 3.5 times higher than that
of the p53fp/fp MEC (Fig. 1C). The basal tyrosine phosphory-
lation intensity of ErbB2 in both cells was compared in order
to further understand the functional activity of ErbB2 overex-
pression in the p53-inactivated MEC. The tyrosine 1248 or 877
residue of ErbB2 is an important ErbB2 autophosphorylation
site [19,20] and there is a correlation between the extent of
phosphorylation and the ErbB2 tyrosine kinase activity. As
shown in Fig. 1D, the phosphorylation of the tyrosine 877
Fig. 1. Eﬀect of p53 inactivation on the expression of ErbB2 in mammary epithelial cells (MEC). (A) Immunoblot analysis of p53. A representative
immunoblot shows the p53 protein in both p53D5,6 MEC (p53MEC) and p53fp/fp MEC (p53+ MEC) incubated with doxorubicin (3 and 10 lM) for
18 h. Each lane was loaded with 20 lg of the cell lysates. An equal loading of the proteins was veriﬁed by actin immunoblot. Scanning densitometry
was used to assess the relative change in ErbB2. (B) p53 reporter gene analysis. Luciferase activities in both p53 MEC and p53+ MEC transiently
transfected with the p53-Luc plasmid, which contains repeated p53 binding sequences, was conﬁrmed using a luminometer. A dual luciferase reporter
gene assay was performed on the lysed cells that had been co-transfected with the p53-Luc (ﬁreﬂy luciferase) and pRL-SV (Renilla luciferase) (a ratio
of 100:1) after exposure to doxorubicin (1 or 3 lM) for 18 h. The activation of the reporter gene was calculated as a relative change in the Renilla
luciferase activity. The data represents the means ± S.D. of 3–4 separate experiments (signiﬁcant compared with the p53 MEC, **P < 0.01). (C)
Immunoblot analysis of ErbB2. Each lane was loaded with 10 lg of the cell lysates. Scanning densitometry was used to assess the relative change in
ErbB2. The data represents the means ± S.D. of three separate samples (signiﬁcant compared with the p53 MEC, **P < 0.01). (D) Immunoblot
analysis of phosphorylated ErbB2 (Tyr-1248 and Tyr-877 phosphorylation).
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MEC compared with those in the p53fp/fp MEC. These results
show that ErbB2 expression is induced in the p53-inactivated
MEC, which might be involved in the increased activity of
ErbB2.
Because primary cultured MECs isolated from p53-inacti-
vated mice was used in this study, it is possible that the en-
hanced ErbB2 expression in p53D5,6 MEC is the result of
additional genetic mutations during the growth period of the
mice. The adenovirus overexpressing Cre recombinase gene
(Ad-Cre) was introduced to the p53fp/fp MECs in order todirectly remove exons 5 and 6 out of the p53 gene. The trun-
cated p53 band was found in the Ad-Cre-treated p53fp/fp
MEC, but not in b-galactosidase expressing adenovirus (Ad-
gal)-treated p53fp/fp MECs. This result reveals that infecting
the cells with Ad-Cre eﬃciently blocks the transcriptional
function of p53 (Fig. 2A).
Further experiments were performed to determine if in vitro
p53 inactivation aﬀected the expression of ErbB2 in MECs.
Exposing the p53fp/fp MECs to Ad-Cre for 24 or 48 h resulted
in a signiﬁcant increase in the ErbB2 protein level (Fig. 2B). In
contrast, the ectopic expression of the p53 gene by Ad-p53
Fig. 2. Induction of ErbB2 in MEC by in vitro p53 inactivation. (A)
Immunoblot analysis of p53 after Cre expressing adenovirus (Ad-Cre)
exposure to p53fp/fp MEC (p53+ MEC) (24 h). b-Galactosidase
expressing adenovirus (Ad-gal) was used for a mock infection purpose.
(B) Immunoblot analysis of ErbB2 after Ad-Cre or Ad-gal exposure to
p53+ MEC for 12–48 h. (C) Immunoblot analyses of p53 and ErbB2
after Ad-Cre or Ad-gal exposure to p53+ MEC (24 h).
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tein levels in p53D5,6 MEC (Fig. 2C). This suggests that ErbB2
expression is directly associated with p53 activity in MECs.
3.2. Requirement of AP-2a induction for the overexpression of
ErbB2 in p53-inactivated MEC
We then focused on how p53 inactivation causes ErbB2
induction in MECs. A family of AP-2 transcription factors
plays a key role in transducing the ErbB2 induction signal
[21,22]. In the ErbB2 gene, Vernimmen et al. [15] reported that
two putative AP-2 binding sites regulate ErbB2 gene expres-
sion at the level of the potent enhancer elements. Therefore,
it was hypothesized that the p53 status is associated with the
activation or expression of the AP-2 transcription factor(s).
The nuclear extracts isolated from the p53D5,6 MEC or
p53fp/fp MEC were probed with the radiolabeled AP-2 putative
binding sequence to determine if the nuclear AP-2 binding pro-
teins are activated in the p53-inactivated MEC. The band of
the slow migrating complex was higher in the samples from
the p53D5,6 MEC than in the wild type MEC (Fig. 3A, left
panel). Competition experiments using an excess (20X) of the
unlabeled AP-2 oligonucleotides conﬁrmed that the increased
band resulted from the enhanced binding of the nuclear AP-
2 proteins (Fig. 3A, left panel). Among the AP-2 family of
transcription factors, AP-2a and AP-2c can bind to the ErbB2
promoter as either homo- or heterodimers. In addition, both
AP-2a and AP-2c are expressed at higher levels in most ErbB2
overexpressing mammary tumor cells [21]. Immunodepletion
experiments were carried out with the nuclear extracts isolatedfrom the p53D5,6 MEC in order to clarify the component(s)
responsible for the enhanced binding. The addition of anti-
AP-2a IgG to the reaction mixture depleted the enhanced
DNA binding and caused a supershifted band (Fig. 3A, right
panel). However, the band intensity was minimally aﬀected
by the addition of antibodies against AP-2c (Fig. 3A, right
panel). This suggests that AP-2a interacts with the AP-2 bind-
ing sequence in the ErbB2 promoter region.
The increases in the band intensity obtained from the gel shift
analyses might be the result of the nuclear migration or the en-
hanced expression of the AP-2 transcription factors. Therefore,
the AP-2a, AP-2b and AP-2c expression levels in cell lysates
from both p53D5,6 MEC and p53fp/fp MEC were determined.
The levels of AP-2a, but not AP-2b or AP-2c in the cell lysates
were signiﬁcantly higher in the p53D5,6 MEC compared with
p53fp/fp MEC (Fig. 3B). Moreover, the nuclear and mRNA lev-
els of AP-2a in p53D5,6 MEC were also higher than that in the
p53fp/fp MEC (Fig. 3B). In order to conﬁrm these results, the
AP-2a levels in the cell lysates were determined after infecting
p53fp/fp MEC with Ad-Cre. The AP-2a expression level was in-
creased by in vitro p53 inactivation (Fig. 3C). This shows that
the selective induction of AP-2a and the subsequent nuclear
accumulation of AP-2a in the p53-inactivated MEC might be
an essential component for the speciﬁc binding complex in
the promoter region of the ErbB2 gene.
Given the role of AP-2 in ErbB2 expression and the activa-
tion of AP-2a in the p53 inactivated MEC, this study next
evaluated whether or not the ErbB2 gene was transcriptionally
activated via the AP-2 binding elements in the p53D5,6 MEC.
Reporter gene assays were performed using the MEC transfec-
ted with p756-Luc, which contain the luciferase cDNA and 756
bp ErbB2 promoter. The luciferase activity in the p53D5,6 MEC
was approximately 7 times higher than that in the p53fp/fp
MEC (Fig. 3D, left panel). pm756-Luc, which contain two mu-
tated AP-2 sites in the p756-Luc reporter vector (pm756-Luc),
was used to conﬁrm the contribution of AP-2 activation to
ErbB2 transactivation in p53-inactivated MEC [15]. After
transfection with pm756-Luc, the enhanced reporter activity
in p53D5,6 MEC was signiﬁcantly diminished (Fig. 3D, left
panel). Moreover, infection of p53fp/fp MEC with Ad-Cre sig-
niﬁcantly increased p756 reporter activity (Fig. 3D, right pa-
nel). These results conﬁrmed that the selective induction of
AP-2a in the p53D5,6 MEC was essential for the upregulation
of the ErbB2 gene.3.3. Role of PKA in AP-2a-mediated ErbB2 induction
in p53-inactivated MEC
The activities or expression levels of most transcription fac-
tors are regulated by distinct members of the kinase family,
which are triggered in response to a variety of stimuli [23].
Extracellular signal-regulated kinase (ERK), p38 kinase and
protein kinase A (PKA) are involved in the activation of
AP-2 [24–26]. Therefore, experiments were carried out to
determine if the ERK, p38 kinase or PKA pathway is associ-
ated with the induction of ErbB2 in p53-inactivated MEC.
The incubation of cells with H-89 (10 lM), a speciﬁc PKA
inhibitor for 24 h completely suppressed ErbB2 expression in
the p53D5,6 MEC (Fig. 4A). On the other hand, treatment of
the cells with U0126 (10 lM, ERK inhibitor) or SB203580
(10 lM, a p38 kinase inhibitor) had no aﬀect on the levels of
the ErbB2 protein (Fig. 4A).
Fig. 3. Role of AP-2a activation in ErbB2 expression. (A) Left panel: Gel shift analysis of the AP-2 transcription complex. Nuclear extracts were
prepared from both p53D5,6 MEC (p53 MEC) and p53fp/fp MEC (p53+ MEC). All lanes contained 8 lg of nuclear extracts and 5 ng of the labeled
AP-2 consensus sequence. Competition studies were carried out by adding a 20-fold excess of unlabeled AP-2 consensus sequence. Right panel:
Immunodepletion studies were carried out by adding an AP-2a or AP-2c antibody (1 lg) to the nuclear extracts of p53 MEC. (B) AP-2 expression
changes in both p53MEC and p53+ MEC. Left panel: Immunoblot analysis of AP-2a, AP-2b or AP-2c in both p53MEC and p53+ MEC. Right
panel: Nuclear levels and mRNA levels of AP-2a in both p53 MEC and p53+ MEC. Nuclear AP-2a was detected immunochemically with speciﬁc
antibody. The AP-2a mRNA expression levels were determined by RT-PCR analysis. The mRNA expression of the S16 ribosomal protein was
comparable among the samples. (C) Immunoblot analysis of AP-2a after Ad-Cre or Ad-gal exposure to p53+ MEC for 12–48 h. (D) Analysis of AP-
2-responsive element in the ErbB2 gene promoter. Left panel: Induction of luciferase activity in p53 MEC transiently transfected with the ErbB2
chimeric gene construct, p756-Luc, which contained the 756 bp promoter region of the ErbB2 gene and luciferase cDNA. A dual luciferase reporter
assay was performed as in panel (B) of Fig. 1. p86-Luc was used as a control vector containing the minimal promoter region. pm756-Luc contains
mutated two AP-2 sites in the p756-Luc reporter vector. The data represents the means ± S.D. of four separate experiments (signiﬁcant compared
with the value from p53 MEC transiently transfected with p756-Luc plasmid, *P < 0.05; **P < 0.01). Right panel: p756-Luc reporter activity in
p53+ MEC infected with Ad-Cre. (Signiﬁcant compared with the Ad-gal treated group, *P < 0.05; **P < 0.01.)
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Fig. 4. Eﬀects of the chemical inhibitors of ERK, p38 kinase and PKA on the induction of ErbB2 in p53-inactivated MEC. (A) The eﬀects of ERK,
p38 kinase and PKA inhibitors on the increase in the ErbB2 level. Both the p53D5,6 MEC (p53 MEC) and p53fp/fp MEC (p53+ MEC) were
incubated with PD98059 (PD, 50 lM), SB203580 (SB, 10 lM) or H-89 (H89, 10 lM) for 24 h and the levels of ErbB2 were immunochemically
assessed. Scanning densitometry was used to assess the relative change in ErbB2. The data represents the means ± S.D. of three separate experiments
(signiﬁcant compared with the p53+ MEC, **P < 0.01; signiﬁcant compared with the p53MEC, **P < 0.01). (B) The eﬀects of ERK, p38 kinase and
PKA inhibitors on the increase in the AP-2a level. (C) PKA enzyme activity in both p53D5,6 MEC (p53MEC) and p53fp/fp MEC (p53+ MEC). The
levels of PKA activity were assessed using Proﬂuor PKA assay kit (Promega).
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posed to each kinase inhibitor in order to identify the possible
relationship between the cellular kinase cascade and the activa-
tion of AP-2a as a transcription factor(s) required for the
induction of ErbB2 in the p53-inactivated MEC. Treatment
of the p53D5,6 MEC with H-89 inhibited the expression of
AP-2a, while U0126 or SB203580 did not aﬀect the expression
of AP-2a (Fig. 4B). Stimulation of the cAMP/PKA pathway
caused an increase in the AP-2 mRNA levels in the hippocam-
pus [27], which suggests that the increased AP-2a transcription
in p53D5,6 MEC results from PKA activation. These results
show that the PKA pathway plays a key role in the activation
of AP-2a-dependent ErbB2 gene expression in the p53-inacti-
vated MEC.
It is unclear if p53 inactivation aﬀects the PKA activity in
MEC. The activity of PKA was assessed using Proﬂuor
PKA assay kit (Promega, Madison, WI). The basal activity
of PKA was 5 times higher in the p53D5,6 MEC than in the
p53fp/fp MEC (Fig. 4C). This shows that PKA is continuously
activated in p53 inactivated MEC.4. Discussion
p53 is a key tumor-suppressor gene that is mutated or lost in
approximately 50% of all human cancer cases worldwide [28].A variety of studies have revealed that p53 exerts its various
functions mainly by regulating gene expression of its target
genes through a consensus DNA-binding site. Most p53 target
genes are involved in mediating cell-cycle arrest and apoptosis.
Thus, dysfunction of p53 results in uncontrolled cell prolifera-
tion and ultimately stimulates carcinogenesis [29]. ErbB2 as a
member of the EGFR family of tyrosine kinases, causes the
proliferation, angiogenesis and metastasis of cancer cells via
the EGF-related pathways [30]. ErbB2 is overexpressed in
25–30% of primary breast cancers and is associated with a
shorter survival, higher recurrence rate and a lower response
to chemotherapy and hormone therapy [31]. In the immuno-
staining analyses using clinical breast cancer tissues, ErbB2
protein overexpression was frequently found with p53 altered
expression [32,33]. In addition, double immunohistochemical
staining results showed p53 and ErbB2 immunoreactivity in
the same cells [33]. Hence, it would be plausible to hypothesize
that p53 function regulates the expression of ErbB2.
We previously generated two diﬀerent mammary gland-spe-
ciﬁc p53 knock-out mice and about two-thirds of tumors from
p53-inactivated mice showed ErbB2 overexpression by immu-
nostaining and Western blot analysis using anti-ErbB2 and
phosphotyrosine antibodies [13]. In the present study, we
showed that ErbB2 was upregulated in p53-inactivated MECs.
The data deﬁnes a novel regulatory loop between p53 as a
tumor suppressor and ErbB2 as a oncogene in MEC. Consid-
J.W. Yang et al. / FEBS Letters 580 (2006) 6501–6508 6507ering pathophysiological condition during breast carcinogene-
sis, p53 inactivation leads to induction of ErbB2, which subse-
quently may cause estrogen-independent growth of mammary
epithelial tissue through exaggerated EGF pathway activation.
Because there are no putative binding site(s) for p53 in the
promoter region of ErbB2 gene, p53 seems not to directly con-
trol transactivation of ErbB2 gene. The transcription factor,
AP-2, plays a key role in regulating erbB2 gene transcription
[22,34]. In the human ErbB2 gene, two putative AP-2 binding
sites are involved in the expression of the ErbB2 gene at the
level of the potent enhancer elements [15]. Therefore, the role
of AP-2 in ErbB2 expression in p53D5,6 MEC was examined.
The present gel-shift assay data support the notion that p53
truncation in MEC activated the AP-2 binding proteins con-
sisting AP-2a, and transcriptionally stimulated ErbB2 gene
expression. The expression levels of AP-2a, but not AP-2b
and AP-2c were selectively enhanced in the p53-inactivated
MEC, which combined with the luciferase-reporter gene and
promoter mutation assays strongly supports the essential role
of AP-2a in the overexpression of ErbB2 in p53D5,6 MEC. It
has been also known that PEA3, a transcription factor in
Ets family, negatively regulates transcription of ErbB2 gene.
It speciﬁcally targets a DNA sequence near the TATA box
on the ErbB2 gene promoter and down-regulates the promoter
activity [35]. The protein levels of PEA3 in total cell lysates
were not diminished, rather increased in p53-inactivated
MEC (data not shown). These results suggest that PEA3 is
not involved in the ErbB2 induction in p53-inactivated MEC.
Despite the identiﬁcation of the essential transcriptional fac-
tor, AP-2 which binds to the ErbB2 promoter, the cellular sig-
naling pathway for the induction of ErbB2 has not been clearly
deﬁned. It has been reported that the activation of two distinct
MAP kinases, ERK and p38 kinase is involved in the process
of AP-2 activation [24,25]. Inhibition of ERK or p38 kinase
did not reduce the AP-2a-mediated ErbB2 expression in
p53D5,6 MEC. Hence, these kinases are unlikely to be respon-
sible for the induction of ErbB2 by p53 inactivation. PKA
has also been shown to increase both the activity and the
expression of AP-2 [26,27]. Whether p53 inactivation led to
activation of PKA was assessed in the present study to address
the physiological signiﬁcance of this kinase. Here, we showed
that basal PKA activity was persistently enhanced in p53D5,6
MEC. This was further supported by the observation that inhi-
bition of PKA by H-89 led to simultaneous blocking of AP-2a
and ErbB2 protein increase. Thus, signaling cascades involving
the PKA activation in p53-inactivated MEC may serve as an
essential mechanism for the induction of ErbB2 gene.
In summary, the present study provides strong evidence that
the ErbB2 expression level is higher in the p53-inactivated
MEC through the selective upregulation of AP-2a, and that
the activation of PKA may be a crucial pathway for AP-2a-
dependent ErbB2 expression.Acknowledgement: This work was supported by a grant from the Re-
gional University Research Program (E-00216, 2004) funded by Korea
Research Foundation (KRF, 2004–2006).References
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